Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Evaluate a health insurer in two linked stages: first determine whether its earnings outlook follows from premiums, medical costs, membership, reserves and capital requirements; then value those earnings using a clearly defined EPS measure and a comparable valuation date. A low price-to-earnings ratio is not persuasive if the forecast assumes an unrealistic medical-cost trend, uses aggressive reserve assumptions or ignores the insurer’s business mix.
1. Define the business before valuing it
Start with the insurer’s latest annual report and quarterly filing. The U.S. Securities and Exchange Commission’s 10-K/10-Q guide explains where to find the business description, management’s discussion and analysis (MD&A), risk factors, liquidity and capital resources, and audited financial statements.
Write down which activities generate the company’s profit. A company concentrated in Medicare Advantage has different rate, benefit, Star Ratings and risk-adjustment exposure from one focused on Medicaid, Affordable Care Act marketplace plans or employer coverage. Some insurers also operate pharmacy, technology, care-delivery or other businesses. Those activities can have different margins and capital needs from underwriting insurance.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Questions to answer from the filings
- What proportion of premium and operating revenue comes from Medicare Advantage, Medicaid, marketplace and commercial products?
- How quickly are membership and premium revenue growing, and which segments are driving the change?
- Are products priced for the current medical-cost trend, or are rates based on older utilization data?
- Are government contracts, markets, products or non-insurance subsidiaries being exited or expanded?
- What risks does management identify around regulation, risk adjustment, rates, network costs, cyber incidents, litigation and capital?
Do not apply one peer’s growth or margin assumptions to another insurer until the segment mix is understood. A different mix can justify a different growth rate, earnings volatility and valuation multiple.
#1 Best Overall
2. Build an earnings bridge from operating drivers
Instead of starting with EPS, reconcile how operating activity becomes net income. A useful bridge tracks the following items for each quarter and full year:
| Bridge item | What to examine | Why it matters |
|---|---|---|
| Premium and other operating revenue | Membership, premium rates, government payments, risk adjustment and product mix | Revenue growth can mask a shift toward lower-margin business or inadequate pricing. |
| Medical costs | Claims paid, utilization, severity, acuity, provider prices and completion estimates | Medical costs usually represent the largest and most volatile expense. |
| Medical or benefit-care ratio | Medical costs divided by the relevant premium or revenue base, using the company’s definition | A rising ratio can overwhelm premium growth; definitions may differ by segment. |
| Administrative expense ratio | Operating expenses relative to revenue, including acquisition and technology spending | Efficiency gains can offset some medical-cost pressure, but cuts may not be durable. |
| Investment income | Portfolio yield, asset duration, realized gains and losses | Investment income can support earnings but is not a substitute for adequate insurance pricing. |
| Taxes and other items | Effective tax rate, interest expense, restructuring, impairments and discontinued operations | These can make reported earnings diverge from operating performance. |
| Diluted shares | Buybacks, issuance, options and convertible securities | EPS can rise through share-count reduction even when total earnings are flat. |
Separate volume from margin. More members or premiums do not automatically produce more profit if claims grow faster, benefit design changes, or membership shifts toward higher-acuity patients. In MD&A, look for explanations involving utilization, acuity, provider pricing, benefit changes, risk adjustment, rate notices and contract changes. Ratio names are not standardized; confirm each numerator and denominator before comparing companies.
3. Read medical and benefit-care ratios with their causes
The medical loss ratio (MLR), medical cost ratio (MCR) or benefit-care ratio is a starting point, not a verdict. A lower percentage generally leaves more premium before administrative costs, but the appropriate level depends on product rules, accounting definitions, benefit design, quality investments and business mix.
Trend, not a single quarter
Plot the ratio by segment for at least several quarters and compare it with management’s target range. Investigate whether movement reflects utilization, inpatient admissions, outpatient services, prescription costs, provider rates, member acuity, coding or risk-adjustment settlements. A favorable quarter can reverse when late claims are reported; an unfavorable quarter can reflect a temporary shock.
Regulatory minimums are product-specific
Alignment Healthcare’s 2025 Form 10-K describes an 85% minimum annual MLR for the Medicare Advantage plans covered in that filing. It states that failing to meet the minimum can require remittance of a portion of premiums to the federal government. Read the applicable product and jurisdictional rules rather than generalizing that threshold to every insurer or line of business. The filing is available at SEC.gov.
Use a company’s explanation to test the forecast
Molina Healthcare reported a consolidated MCR of 91.7% for 2025 versus 89.1% in 2024. Its 2025 Form 10-K attributed the increase mainly to utilization above expectations and acuity shifts, and described the ratio as above its long-term target range. The relevant question is whether those drivers are recurring and whether pricing or benefit changes can catch up—not whether 91.7% is universally good or bad. See the filing at SEC.gov.
4. Treat management guidance as a hypothesis
Guidance is an expectation, not an achieved result. Create a dated record containing the current full-year GAAP EPS outlook, adjusted EPS outlook, revenue and membership assumptions, the preceding outlook and the latest actual quarter. Then identify exactly what changed.
- Capture the original baseline. Save the first annual outlook and the assumptions management disclosed.
- Capture every revision. Mark whether guidance was raised, maintained, narrowed or cut, and whether the change affects GAAP, adjusted results or both.
- Identify operating drivers. Record the implied medical-cost trend, membership, pricing, risk adjustment, benefit design, quality-program payments and administrative savings.
- Compare with actual evidence. Check whether recent MLR or MCR, enrollment, utilization and cash flow support those assumptions.
- Build independent cases. Model at least a base case and a downside case with explicit medical-cost, membership and margin assumptions.
Keep GAAP and adjusted EPS separate
Adjusted EPS may exclude items such as restructuring, impairments or other charges. It can help analyze recurring operations, but it is not interchangeable with GAAP EPS. Preserve the reconciliation and define which denominator you use in any valuation.
Rank #3
Illustration: Humana’s July 2026 revision
In its July 29, 2026 second-quarter release, Humana revised fiscal-year 2026 GAAP EPS guidance to “at least $6.52” from “at least $8.36,” while affirming adjusted EPS guidance of “at least $9.00.” The company said the anticipated year-over-year adjusted-EPS decline reflected the Star Ratings headwind for Bonus Year 2026, net of mitigation. These are company-specific figures, not industry benchmarks. The release is at SEC.gov. An analyst should preserve both EPS measures, investigate the Star Ratings effect and test how much mitigation is already embedded in the outlook.
5. Inspect reserves and claims development
Claims are estimated after services occur. The insurer records liabilities for reported claims and for incurred-but-not-reported (IBNR) claims, then updates those estimates as claims arrive. Reserve releases can lift current earnings; adverse development can reduce them.
Reserve-quality checklist
- Read the medical-claims-liability and IBNR methodology, including completion factors and trend assumptions.
- Compare prior-period reserve development across several years, not just the latest quarter.
- Ask whether assumptions changed because of utilization, provider prices, coding, acuity or data revisions.
- Look for premium-deficiency reserves when expected future claims and expenses exceed premiums.
- Review risk-adjustment receivables, payables and true-ups, which can move between periods.
- Check whether management provides sensitivity information or identifies unusually uncertain estimates.
Centene reported $20.3 billion in medical claims liabilities in its July 28, 2026 second-quarter results. That balance is a scale indicator, not evidence by itself that reserves are excessive or inadequate. The same release gave total-revenue guidance of $193.5 billion to $197.5 billion. Read both figures with the company’s membership, utilization and reserve explanations at Centene’s investor-relations release.
Free tools Windows power users keep installed
One-click scans. No signup required.
6. Examine capital, liquidity and cash conversion
Insurance subsidiaries must maintain capital under state and program rules. The parent company’s cash is not the same as regulated-subsidiary capital, and neither is the same as temporary working-capital cash generated by timing differences.
What to locate
- Debt maturities, interest costs and covenant requirements.
- Holding-company cash and the ability to receive dividends from regulated subsidiaries.
- Statutory capital, risk-based-capital information and required capital contributions.
- Claims liabilities and receivables that may consume cash before earnings are collected.
- Restrictions on dividends, acquisitions and share repurchases.
Assess buybacks or acquisitions only after considering sustainable cash generation and capital requirements. There is no single cross-company capital threshold that establishes fair value; the relevant requirement depends on the issuer’s regulated entities, states, products and risk profile.
7. Choose a consistent EPS basis before calculating P/E
The SEC’s Investor.gov definition describes price-to-earnings (P/E) as stock price divided by earnings per share. The formula is simple; selecting the denominator is not.
| EPS basis | Definition | Primary use | Main caution |
|---|---|---|---|
| Trailing GAAP EPS | Reported GAAP EPS for the latest completed period, commonly the past four quarters | Uses actual results | May include unusual charges or a cycle that does not represent future earnings. |
| Forward GAAP EPS | Expected GAAP EPS for a specified future period | Values anticipated earnings | Depends on forecast credibility and the exact forecast date. |
| Adjusted EPS | Company-defined EPS excluding specified items | Can isolate management’s view of recurring operations | Definitions differ; exclusions may recur or obscure economic costs. |
State the share-price date, EPS period, currency, share count and whether EPS is GAAP or adjusted. Never compare one insurer’s forward adjusted P/E with another’s trailing GAAP P/E and call the result a peer discount. Recalculate both on the same basis or clearly label the limitation.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Use scenarios instead of a single target price
A scenario table makes assumptions visible:
| Case | Medical-cost assumption | Membership/pricing assumption | EPS treatment | Valuation output |
|---|---|---|---|---|
| Base | Management’s stated trend, adjusted only for evidence from recent quarters | Current enrollment and approved rates | Forward GAAP or consistently reconciled adjusted EPS | Price divided by base EPS |
| Downside | Higher utilization, acuity or provider-price trend | Slower growth, weaker mix or delayed rate adequacy | Lower EPS after stated cost and reserve effects | Price divided by downside EPS |
| Upside | Utilization normalizes and pricing catches up | Membership and risk adjustment meet or exceed plan | Higher EPS only where operating evidence supports it | Price divided by upside EPS |
The resulting multiple is an output of assumptions, not an objective price target. Present the assumptions and show how sensitive the multiple is to EPS changes.
Best Value
8. Compare peers on risk-adjusted economics
Peer analysis is useful only when the comparison controls for differences that change expected earnings and required capital.
| Comparison axis | Evidence to collect | Valuation implication |
|---|---|---|
| Government versus commercial mix | Membership and revenue by Medicare Advantage, Medicaid, marketplace and employer products | Changes exposure to rate cycles, regulation and risk adjustment. |
| Growth and mix | Enrollment, premium growth, product exits and market expansion | Fast growth can increase earnings or dilute margins. |
| Medical-cost trend | MLR/MCR, utilization, acuity, provider prices and target ranges | Determines whether pricing is adequate. |
| Administrative efficiency | Expense ratio, technology spending and acquisition costs | Shows potential operating leverage and execution risk. |
| Reserve and risk-adjustment uncertainty | IBNR development, true-ups and premium-deficiency reserves | Raises or lowers confidence in reported and forecast earnings. |
| Capital and leverage | Debt, liquidity, regulated capital and dividend restrictions | Constrains buybacks, acquisitions and distributions. |
| Earnings volatility | History of guidance revisions, impairments and ratio swings | May warrant a lower multiple even when growth is similar. |
| Valuation definition | Price date, trailing/forward period and GAAP/adjusted EPS | Prevents false discounts caused by inconsistent denominators. |
A lower peer multiple can reflect higher medical-cost risk, weaker capital, slower growth or less reliable guidance. A higher multiple can be justified by more durable margins, stronger cash conversion or lower forecast uncertainty. No single ratio establishes fair value.
9. Interpret current disclosures without losing context
Oscar Health: a year-over-year MLR comparison
Oscar reported a 79.2% MLR for the second quarter of 2026 versus 91.1% for the second quarter of 2025, alongside operating earnings of $388.6 million compared with an operating loss of $230.5 million. Oscar noted that the prior-year quarter included the first-half 2025 effect of a risk-adjustment true-up caused by higher average market morbidity. The comparison therefore requires that adjustment context; it is not proof that the entire improvement is a recurring margin gain. See the company’s release at Oscar’s investor-relations site.
How to use examples correctly
These disclosures demonstrate the process: preserve the period, definition and explanation; separate one-time true-ups from underlying trends; and test whether the next year’s guidance assumes the same benefit. They are not industry-wide benchmarks or substitutes for reviewing each issuer’s filings.
10. Common analytical errors and fixes
- Using revenue growth as an earnings proxy: Reconcile growth with medical and administrative ratios.
- Quoting one MLR or MCR number: Identify the segment, denominator, period and operational cause.
- Mixing GAAP and adjusted EPS: Keep separate columns and document every adjustment.
- Accepting the latest guidance midpoint without testing it: Compare it with prior guidance and recent actual utilization, acuity and claims.
- Ignoring reserve development: Track prior-period releases and adverse development before treating earnings as durable.
- Treating parent cash as excess capital: Separate holding-company liquidity from regulated-subsidiary requirements.
- Comparing mismatched P/Es: Align price date, forecast period, accounting basis and share count.
- Assuming a lower multiple means undervaluation: Identify the risk or growth difference that the market may be pricing.
- Turning management’s statement into evidence: A CEO’s strategy explains intent; claims, cash flow and filing data test execution.
11. A repeatable review checklist
- Download the latest 10-K, 10-Q and earnings release.
- Map segments, products, government exposure and non-insurance operations.
- Build a multi-period table for membership, premium, medical costs, MLR/MCR, administrative expenses, investment income, taxes and diluted shares.
- Record the original and current GAAP and adjusted guidance, including every stated driver.
- Test medical-cost, membership, pricing, risk-adjustment and Star Ratings assumptions against recent results.
- Review IBNR, reserve development, premium-deficiency reserves and risk-adjustment balances.
- Separate parent cash, regulated capital, debt and dividend restrictions.
- Select one EPS definition and valuation date for the company and every peer.
- Calculate base, downside and upside P/E outcomes, showing the assumptions behind each EPS.
- Write the investment conclusion as a confidence assessment: which assumptions are supported, which are uncertain, and what future disclosure would change the view.
This process produces a valuation range tied to operating evidence rather than a multiple selected in isolation.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
